CCM
AUTL

CAAS Capital Management’s Autolus Therapeutics AUTL Stock Holding History

CAAS Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-322,795
Closed -$613K – 709
2022
Q4 		$613K Buy
+322,795
New +$816K 0.04% 364
2021
Q2 		– Sell
-223,366
Closed -$1.28M – 1035
2021
Q1 		$1.28M Buy
+223,366
New +$1.65M 0.01% 721

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

CAAS Capital Management's AUTL Position: Q1 2023 in Review

CAAS Capital Management sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 322,795 shares — an estimated $613K sold.

CAAS Capital Management first reported a position in AUTL in Q1 2021 and held it in 2 quarters. The position peaked at $1.28M in Q1 2021. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

  • CAAS Capital Management reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 322,795 Autolus Therapeutics shares in Q1 2023, an estimated $613K.
  • CAAS Capital Management first reported a position in Autolus Therapeutics in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Autolus Therapeutics position peaked at $1.28M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.